Showing results (321-330 of 381) with videos related to

Sort By:
Pageof 39
Virus Research|October 16, 1999
A new variant of GB virus C/hepatitis G virus (GBV-C/HGV) from South AfricaM A Sathar, P N Soni, R Pegoraro, et al.
European Journal of Nuclear Medicine|January 1, 1987
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanomaT Cerny, S E Owens, S A Mackenzie, et al.
Scientific Reports|July 10, 2015
A High Throughput Ambient Mass Spectrometric Approach to Species Identification and Classification from Chemical Fingerprint SignaturesRabi A Musah, Edgard O Espinoza, Robert B Cody, et al.
Journal of Chromatography. A|April 15, 2015
Non-targeted analysis of electronics waste by comprehensive two-dimensional gas chromatography combined with high-resolution mass spectrometry: Using accurate mass information and mass defect analysis to explore the dataMasaaki Ubukata, Karl J Jobst, Eric J Reiner, et al.
Nature Biotechnology|October 5, 2022
Modular, programmable RNA sensing using ADAR editing in living cellsK Eerik Kaseniit, Noa Katz, Natalie S Kolber, et al.
The Journal of General Virology|July 1, 1995
Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study GroupD B Smith, J Mellor, L M Jarvis, et al.
Lancet (London, England)|August 24, 1991
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapyD B Smith, E S Newlands, G J Rustin, et al.
British Journal of Cancer|June 1, 1988
A phase I and pharmacokinetic study of amphethinileD B Smith, C Ewen, J Mackintosh, et al.
Journal of Gerontology|July 1, 1980
Age differences in the contingent negative variation (CNV): reduced frontal activity in the elderlyH J Michalewski, L W Thompson, D B Smith, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapyD B Smith, E S Newlands, G J Rustin, et al.
Pageof 39